Skip to search formSkip to main contentSkip to account menu

Carboplatin-Taxol-Bevacizumab Regimen

Known as: Carbo-Taxol-Avastin Regimen, carboplatin-paclitaxel-bevacizumab regimen 
A chemoimmunotherapy regimen consisting of carboplatin, paclitaxel and bevacizumab used to treat advanced stage, non-small cell lung cancer which is… 
National Institutes of Health

Related topics

Related topics

4 relations
CarboplatinNon-Small Cell Lung CarcinomaPaclitaxelbevacizumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer.
2018
2018
Resultados anatómicos e funcionais de olhos com edema macular diabético após conversão de terapêutica com bevacizumab para aflibercept
IntroducaoO edema macular diabetico (EMD), uma manifestacao da retinopatia diabetica, e a principal causa de perda da acuidade… 
Review
2017
Review
2017
Pembrolizumab for the treatment of non-small cell lung cancer
ABSTRACT Introduction: In the last years, a spectacular development of immunotherapeutic agents aimed at the PD-1/PD-L1 axis has… 
2017
2017
Metastatic ovarian tumor of a lung cancer at the hospital center of Chauny (France): a case report
The ovary is an organ that can be the site of metastases for many cancers. In general, malignant ovarian tumors are primary… 
2016
2016
Brustkrebs: Bevacizumab / Capecitabin vs. Bevacizumab / Paclitaxel
2014
2014
Correlation of molecular subtypes with survival in AVAglio (bevacizumab [Bv] and radiotherapy [RT] and temozolomide [T] for newly diagnosed glioblastoma [GB]).
2001^ Background: Factors that correlate the extent of clinical benefit with anti-VEGF therapy are poorly understood. Two phase 3… 
2014
2014
L’association paclitaxel–bevacizumab est une alternative intéressante dans le traitement des cancers bronchopulmonaires non épidermoïdes avancés en troisième ligne et plus
2011
2011
5073 POSTER Bevacizumab (Bev) Combined With Paclitaxel (Pac) as First-line Therapy for Metastatic Triple-negative Breast Cancer (TNBC) -Analysis of 147 Patients (pts) Treated in Routine Oncology…
2010
2010
Salvage treatment in metastatic breast cancer (MBC) with weekly paclitaxel (P) plus biweekly bevacizumab (B).
e11503 Background: The dose and schedule of paclitaxel administration have been evolving during the last years. Weekly paclitaxel… 
Review
2009
Review
2009
Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)